scispace - formally typeset
M

Mauro Biffoni

Researcher at Istituto Superiore di Sanità

Publications -  98
Citations -  10752

Mauro Biffoni is an academic researcher from Istituto Superiore di Sanità. The author has contributed to research in topics: Stem cell & Cancer stem cell. The author has an hindex of 34, co-authored 88 publications receiving 9812 citations. Previous affiliations of Mauro Biffoni include Sapienza University of Rome.

Papers
More filters
Journal ArticleDOI

Identification and expansion of human colon-cancer-initiating cells

TL;DR: It is concluded that colorectal cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells, which should therefore be the target of future therapies.
Journal ArticleDOI

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

TL;DR: A variable number (range 20–90%, mean 60.7%) of endothelial cells in glioblastoma carry the same genomic alteration as tumour cells, indicating that a significant portion of the vascular endothelium has a neoplastic origin.
Journal ArticleDOI

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.

TL;DR: It is proposed thatmiR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion through the regulation of BCL2 and CCND1.
Journal ArticleDOI

CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis

TL;DR: It is shown that all colorectal cancer stem cells (CR-CSCs) express CD44v6, which is required for their migration and generation of metastatic tumors, and phosphatidylinositol 3-kinase (PI3K) inhibition selectively killed CD 44v6 CR-C SCs and reduced metastatic growth.
Journal ArticleDOI

The Promyelocytic Leukemia Zinc Finger–MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms

TL;DR: In vitro and in vivo functional studies, including the use of antisense "antagomir" oligonucleotides, confirmed the key role of miR-221/-222 in regulating the progression of human melanoma; this suggests that targeted therapies suppressing miR -221/222 may prove beneficial in advanced melanoma.